We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Evgen Pharma Appoints Chief Medical Officer

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

Evgen Pharma plc has announced the appointment of Dr Hamina J Patel MB BCh MSc MRCPI as Chief Medical Officer.

Dr Patel is a pharmaceutical executive with more than 15 years’ industry experience, leading global cross functional teams in the development and commercialization of drugs primarily within the field of oncology.

Dr Patel was previously Director of Drug Development, Oncology, at Johnson and Johnson, where she helped to build a broad and differentiated portfolio of indications for the cancer drug VELCADE® and was instrumental in the success of a new indication (the second-line treatment of mantle cell lymphoma) based on a Phase II clinical study in more than 35 countries. She received numerous awards for her contribution to the Oncology group at Johnson and Johnson, including a Standard of Leadership award.

In addition to her small molecule expertise, Dr Patel has worked extensively in the development of biopharmaceuticals at Celltech and at Chugai.

Dr Patel qualified as a physician in 1990 and worked for almost ten years in hospitals around the UK before moving into the pharmaceutical industry.

Dr Stephen Franklin, Evgen Pharma’s CEO, commented: “We are delighted to announce the appointment of Dr Hamina Patel as Evgen’s Chief Medical Officer. Hamina has an impressive track record at global pharmaceutical companies and a breadth of relevant clinical experience. Her appointment strengthens the core team at Evgen and will be of great value in the delivery of our upcoming Phase II clinical trials in metastatic breast cancer and in subarachnoid haemorrhage, both of which are on track to begin this year.”